A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.

[1]  A. Camm,et al.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.

[2]  Ching‐Jen Wang,et al.  Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. , 2014, Thrombosis research.

[3]  G. Lip,et al.  Edoxaban: a focused review of its clinical pharmacology. , 2014, European heart journal.

[4]  Jun Zhu,et al.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.

[5]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[6]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[7]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[8]  R. de Caterina,et al.  Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) , 2013, Thrombosis and Haemostasis.

[9]  G. Raskob,et al.  Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement , 2010, Thrombosis and Haemostasis.

[10]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[11]  R. Rokseth.  CLINICAL CONSIDERATIONS IN QUINIDINE THERAPY OF CHRONIC AURICULAR FIBRILLATION. A STUDY OF 200 UNSELECTED PATIENTS--WITH FOLLOW-UP. , 2009, Acta medica Scandinavica.

[12]  R. Macfadyen,et al.  Routine Unselected Access to Day Case Electrical Cardioversion of Persistent Atrial Fibrillation: Anticoagulant Preparation is the Key Factor , 2004, Scottish medical journal.

[13]  J. Mayet,et al.  Anticoagulation for cardioversion of atrial fibrillation. , 2002, Minerva cardioangiologica.

[14]  Rimm,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[15]  R. D. Murray,et al.  Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study. , 1998, The American journal of cardiology.

[16]  F. Loop,et al.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.

[17]  Denis Roy,et al.  Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. , 1986, American heart journal.

[18]  O. Orning,et al.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.

[19]  L. Mcdonald,et al.  Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. , 1967, British heart journal.

[20]  J. Jude,et al.  Electroshock for atrial flutter and atrial fibrillation. Follow-up studies on 50 patients. , 1965, JAMA.

[21]  H. Mcintosh,et al.  EXPERIENCE WITH "CARDIOVERSION" OF ATRIAL FIBRILLATION AND FLUTTER. , 1964, The American journal of cardiology.

[22]  B. Lown,et al.  "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. , 1963, The New England journal of medicine.

[23]  J. Haft,et al.  Edoxaban versus warfarin for venous thromboembolism. , 2014, The New England journal of medicine.

[24]  G. Lip,et al.  Vitamin K antagonists in heart disease: Current status and perspectives (Section III) , 2013, Thrombosis and Haemostasis.

[25]  R. Cebul,et al.  Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. , 1995, American heart journal.